← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › OTHER ANTINEOPLASTIC AGENTS › Other antineoplastic agents
nirogacestat
L01XX81
Adult Dosing
- 150 mg orally twice daily with or without food until disease progression or unacceptable toxicity
Pediatric Dosing
- Safety and efficacy have not been established in pediatric patients
Indications
- Treatment of adult patients with progressing desmoid tumors who require systemic therapy
Mechanism of Action
- Gamma-secretase inhibitor that blocks the cleavage of transmembrane proteins including Notch, reducing tumor growth and proliferation in desmoid tumors
Contraindications
- Hypersensitivity to nirogacestat or any of its excipients
- Pregnancy due to the risk of fetal harm
Adverse Reactions
- Diarrhea
- Ovarian toxicity (ovarian dysfunction/amenorrhea)
- Fatigue
- Hypophosphatemia
- Nausea
- Headache
- Abdominal pain
- Cough
- Alopecia
- Stomatitis
- Elevated liver enzymes
Drug Interactions
- Strong CYP3A4 inhibitors increase nirogacestat exposure; avoid coadministration or reduce nirogacestat dose
- Moderate CYP3A4 inhibitors increase nirogacestat exposure; reduce dose accordingly
- Strong or moderate CYP3A4 inducers decrease nirogacestat exposure; avoid coadministration
- Coadministration with sensitive CYP3A4 substrates may alter their plasma concentrations
Curated Content: Needs Vetting Before Put to Clinical Use